Clinical Trial Update: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the safety and efficacy of a triple-drug combination (Zimberelimab, Domvanalimab, and Etrumadenant) in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Domvanalimab (domvanalimab)
• Etrumadenant (etrumadenant)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non Small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING